A Systematic Review of Neoadjuvant Therapy Compared to the “Resection First” Approach for Patients with Borderline Resectable Pancreatic Adenocarcinoma

Paul G. Toomey, Sharona Ross, Shalin Shah, Alexander S. Rosemurgy

Florida Cancer Specialists, Tampa, USA.
The Southeastern Center for Digestive Disorders & Pancreatic Cancer, Advanced Minimally Invasive & Robotic Surgery, Florida Hospital Tampa, Tampa, USA.

DOI: 10.4236/jct.2014.51012                

Abstract

Background: Survival for patients with pancreatic adenocarcinoma continues to be poor. Patients with pancreatic adenocarcinoma that is deemed borderline resectable have imaging that shows disease involvement of the portal vein and/or superior mesenteric vein that is amenable to reconstruction or abutment (≤180 degrees) of the superior mesenteric artery. The best initial treatment for patients with borderline resectable pancreatic adenocarcinoma has yet to be determined. Proponents of neoadjuvant therapy purport its utility for patients with borderline resectable pancreatic adenocarcinoma with the intention of increasing the likelihood of a microscopically negative (R0) margin, but the consequences of this approach are not established. This study was undertaken to systematically review the outcomes for patients with borderline resectable pancreatic adenocarcinoma to compare neoadjuvant therapy to a “resection first” approach. Methods: A MEDLINE/PubMed search was undertaken to find all studies regarding patients who underwent neoadjuvant therapy for patients with borderline resectable pancreatic adenocarcinoma. Results: A total of 112 studies were found regarding borderline resectable pancreatic cancer. Fourteen studies contained cohorts of patients with borderline resectable pancreatic adenocarcinoma who received neoadjuvant therapy (n = 471 patients) or a resection-first approach (n = 76 patients). Resection after neoadjuvant therapy was undertaken for 233 (49%) patients. Neoadjuvant therapy followed by an R0 resection occurred for 42% of patients. For patients who underwent resection first, 71% (54/76) had an R0 margin. Conclusion: Patients with borderline resectable pancreatic adenocarcinoma were more often found to undergo neoadjuvant therapy than a “resection first” approach in the available literature. Although neoadjuvant therapy portends a high rate of R0 resections, less than half of the patients who undergo neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma undergo resection. Patients who undergo “resection first” for borderline resectable pancreatic adenocarcinoma have an increased chance for a resection and an R0 margin compared to patients who undergo neoadjuvant therapy for borderline pancreatic adenocarcinoma.

Keywords

Adenocarcinoma; Borderline; Cancer; Chemotherapy; Chemoradiation; Neoadjuvant; Pancreatic; Resectable

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	D. Henne-Bruns, I. Vogel, J. Luttges, et al., “Ductal Adenocarcinoma of the Pancreas Head: Survival after Regional versus Extended Lymphadenectomy,” Hepatogastroenterology, Vol. 45, No. 21, 1998, pp. 855-866.
[2]	C. D. Johnson, G. Schwall, J. Flechtenmacher and M. Trede, “Resection for Adenocarcinoma of the Body and Tail of the Pancreas,” British Journal of Surgery, Vol. 80, No. 9, 1993, pp. 1177-1179. http://dx.doi.org/10.1002/bjs.1800800937
[3]	M. Mukaiya, K. Hirata, T. Satoh, et al., “Lack of Survival Benefit of Extended Lymph Node Dissection for Ductal Adenocarcinoma of the Head of the Pancreas: Retrospective Multi-Institutional Analysis in Japan,” World Journal of Surgery, Vol. 22, No. 3, 1998, pp. 248-252. http://dx.doi.org/10.1007/ s002689900378
[4]	S. P. Cleary, R. Gryfe, M. Guindi, et al., “Prognostic Factors in Resected Pancreatic Adenocarcinoma: Analysis of Actual 5-Year Survivors,” Journal of the American College of Surgeons, Vol. 198, No. 5, 2004, pp. 722-731. http://dx.doi.org/10.1016/j.jamcollsurg.2004.01.008
[5]	J. Hernandez, J. Mullinax, W. Clark, et al., “Survival after Pancreaticoduodenectomy Is Not Improved by Extending Resections to Achieve Negative Margins,” Annals of Surgery, Vol. 250, No. 1, 2009, pp. 76-80. http://dx.doi.org/10.1097/01.sla.0000259391.84304.2b
[6]	C. P. Raut, J. F. Tseng, C. C. Sun, et al., “Impact of Resection Status on Pattern of Failure and Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma,” Annals of Surgery, Vol. 246, No. 1, 2007, pp. 52-60. http://dx.doi.org/10.1097/01.sla.0000259391.84304.2b
[7]	P. Toomey, J. Hernandez, C. Morton, et al., “Resection of Portovenous Structures to Obtain Microscopically Negative Margins during Pancreaticoduodenectomy for Pancreatic Adenocarcinoma Is Worthwhile,” American Journal of Surgery, Vol. 75, No. 9, 2009, pp. 804-809.
[8]	J. F. Helm, B. A. Centeno, D. Coppola, et al., “Outcomes Following Resection of Pancreatic Adenocarcinoma: 20-Year Experience at a Single Institution,” Cancer Control, Vol. 15, No. 4, 2008, pp. 288-294.
[9]	P. Toomey, J. Hernandez, F. Golkar, et al., “Pancreatic Adenocarcinoma: Complete Tumor Extirpation Improves Survival Benefit despite Larger Tumors for Patients Who Undergo Distal Pancreatectomy and Splenectomy,” Journal of Gastrointestinal Surgery, Vol. 16, No. 2, 2012, pp. 376-381.
[10]	G. R. Varadhachary, E. P. Tamm, J. L. Abbruzzese, et al., “Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy,” Annals of Surgical Oncology, Vol. 13, No. 8, 2006, pp. 1035-1046. http://dx.doi.org/10.1245/ASO.2006.08.011
[11]	G. R. Varadhachary, E. P. Tamm, C. Crane, et al., “Borderline Resectable Pancreatic Cancer,” Current Treatment Options in Gastroenterology, Vol. 8, No. 5, 2005, pp. 377-384. http://dx.doi.org/10.1007/ s11938-005-0040-x
[12]	M. H. Katz, P. W. Pisters, D. B. Evans, et al., “Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease,” Journal of the American College of Surgeons, Vol. 206, No. 5, 2008, pp. 833-846. http://dx.doi.org/10.1016/j.jamcollsurg.2007.12.020
[13]	M. P. Callery, K. J. Chang, E. K. Fishman, et al., “Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement,” Annals of Surgical Oncology, Vol. 16, No. 7, 2009, pp. 1727-1733. http://dx.doi.org/10.1245/s10434-009-0408-6
[14]	H. A. Burris III, M. J. Moore, J. Andersen, et al., “Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial,” Journal of Clinical Oncology, Vol. 15, No. 6, 1997, pp. 2403-2413.
[15]	D. Tassinari, “Surrogate End Points of Quality of Life Assessment: Have We Really Found What We Are Looking for?” Health and Quality of Life Outcomes, Vol. 1, 2003, p. 71. http://dx.doi.org/10.1186/ 1477-7525-1-71
[16]	A. Andriulli, V. Festa, E. Botteri, et al., “Neoadjuvant/ Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-Analysis of Prospective Studies,” Annals of Surgical Oncology, Vol. 19, No. 5, 2012, pp. 1644-1662. http://dx.doi.org/10.1245/s10434-011-2110-8
[17]	D. Habermehl, K. Kessel, T. Welzel, et al., “Neoadjuvant Chemoradiation with Gemcitabine for Locally Advanced Pancreatic Cancer,” Radiation Oncology, Vol. 7, 2012, p. 28. http://dx.doi.org/10.1186/ 1748-717X-7-28
[18]	S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, et al., “Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Response and Resection Percentages,” PLOS Medicine, Vol. 7, No. 4, 2010, Article ID: e1000267. http://dx.doi.org/10.1371/journal.pmed. 1000267
[19]	C. J. Yeo, J. L. Cameron, K. D. Lillemoe, et al., “Pancreaticoduodenectomy for Cancer of the Head of the Pancreas. 201 Patients,” Annals of Surgery, Vol. 221, No. 6, 1995, pp. 721-731. http://dx.doi.org/10.1097/00000658-199506000-00011
[20]	P. Toomey, C. Childs, K. Luberice, S. Ross and A. Rosemurgy, “Nontherapeutic Celiotomy Incidence Is Not Affected by Volume of Pancreaticoduodenectomy for Pancreatic Adenocarcinoma,” American Journal of Surgery, Vol. 79, No. 8, 2013, pp. 781-785.
[21]	L. Chang, D. Stefanidis, W. S. Richardson, et al., “The Role of Staging Laparoscopy for Intraabdominal Cancers: An Evidence-Based Review,” Surgical Endoscopy, Vol. 23, No. 2, 2009, pp. 231-241. http://dx.doi.org/10.1007/s00464-008-0099-2
[22]	D. D. Von Hoff, R. K. Ramanathan, M. J. Borad, et al., “Gemcitabine plus Nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial,” Journal of Clinical Oncology, Vol. 29, No. 34, 2011, pp. 4548-4554. http://dx.doi.org/10.1200/JCO.2011.36.5742
[23]	J. M. Pimiento, T. Hutchinson, J. M. Weber, M. R. Patel, P. J. Hodul, M. D. Chuong, G. M. Springett, S E. Hoffe, R. C. Karl, B. Centeno, J. Klapman, R. Shridhar, D. Chen and M. P. Malafa, “Multimodality Therapy for Borderline Resectable Pancreatic Cancer: A Single-Institution Experience,” Journal of Clinical Oncology, Vol. 30, Suppl. 4, 2012, Abstract 280.
[24]	C. M. Kang, Y. E. Chung, J. Y. Park, et al., “Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer,” Journal of Gastrointestinal Surgery, Vol. 16, No. 3, 2012, pp. 509-517. http://dx.doi.org/10.1093/annonc/mds109
[25]	J. M. Pipas, B. I. Zaki, M. M. McGowan, et al., “Neoadjuvant Cetuximab, Twice-Weekly Gemcitabine, and Intensity-Modulated Radiotherapy (IMRT) in Patients with Pancreatic Adenocarcinoma,” Annals of Oncology, Vol. 23, No. 11, 2012, pp. 2820-2827. http://dx.doi.org/10.1093/annonc/mds109
[26]	N. D. Arvold, D. P. Ryan, A. Niemierko, et al., “LongTerm Outcomes of Neoadjuvant Chemotherapy before Chemoradiation for Locally Advanced Pancreatic Cancer,” Cancer, Vol. 118, No. 12, 2012, pp. 3026-3035.
[27]	M. D. Chuong, T. J. Hayman, M. R. Patel, et al., “Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment after Neoadjuvant GTX-RT in BorderlineResectable Pancreatic Cancer,” Gastrointestinal Cancer Research, Vol. 4, No. 4, 2011, pp. 128-134.
[28]	M. Patel, S. Hoffe, M. Malafa, et al., “Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer,” Journal of Surgical Oncology, Vol. 104, No. 2, 2011, pp. 155-161. http://dx.doi.org/10.1002/jso.21954
[29]	J. B. Stokes, N. J. Nolan, E. B. Stelow, et al., “Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer,” Annals of Surgical Oncology, Vol. 18, No. 3, 2011, pp. 619-627. http://dx.doi.org/10.1245/s10434-010-1456-7
[30]	S. Takahashi, T. Kinoshita, M. Konishi, et al., “Borderline Resectable Pancreatic Cancer: Rationale for Multidisciplinary Treatment,” Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 18, No. 4, 2011, pp. 567-574. http://dx.doi.org/10.1007/s00534-011-0371-z
[31]	R. J. McClaine, A. M. Lowy, J. J. Sussman, et al., “Neoadjuvant Therapy May Lead to Successful Surgical Resection and Improved Survival in Patients with Borderline Resectable Pancreatic Cancer,” HPB (Oxford), Vol. 12, No. 1, 2010, pp. 73-79. http://dx.doi.org/10.1111/j.1477-2574.2009.00136.x
[32]	M. Piperdi, T. P. McDade, J. K. Shim, et al., “A Neoadjuvant Strategy for Pancreatic Adenocarcinoma Increases the Likelihood of Receiving All Components of Care: Lessons from a Single-Institution Database,” HPB (Oxford), Vol. 12, No. 3, 2010, pp. 204-210.
[33]	K. M. Brown, V. Siripurapu, M. Davidson, et al., “Chemoradiation Followed by Chemotherapy before Resection for Borderline Pancreatic Adenocarcinoma,” American Journal of Surgery, Vol. 195, No. 3, 2008, pp. 318-321. http://dx.doi.org/10.1016/j.amjsurg.2007.12.017
[34]	J. L. Marti, H. S. Hochster, S. P. Hiotis, et al., “Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer,” Annals of Surgical Oncology, Vol. 15, No. 12, 2008, pp. 3521-3531. http://dx.doi.org/10.1245/s10434-008-0152-3
[35]	W. Small Jr., J. Berlin, G. M. Freedman, et al., “Full-Dose Gemcitabine with Concurrent Radiation Therapy in Patients with Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial,” Journal of Clinical Oncology, Vol. 26, No. 6, 2008, pp. 942-947. http://dx.doi.org/10.1200/JCO.2007.13.9014
[36]	P. Massucco, L. Capussotti, A. Magnino, et al., “Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival,” Annals of Surgical Oncology, Vol. 13, No. 9, 2006, pp. 1201-1208. http://dx.doi.org/10.1245/s10434-006-9032-x
[37]	J. M. Pipas, R. J. Barth Jr., B. Zaki, et al., “Docetaxel/ Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients with Pancreatic Adenocarcinoma,” Annals of Surgical Oncology, Vol. 12, No. 12, 2005, pp. 995-1004. http://dx.doi.org/10.1245/ASO.2005.04.503
[38]	S. V. Shrikhande, S. Arya, S. G. Barreto, et al., “Borderline Resectable Pancreatic Tumors: Is There a Need for Further Refinement of This Stage?” Hepatobiliary & Pancreatic Diseases International, Vol. 10, No. 3, 2011, pp. 319-324. http://dx.doi.org/10.1016/S1499-3872(11)60053-2